by Laura Bonnell | Jan 11, 2021 | News
Warrior Wednesday amplifies the voice of the cystic fibrosis community worldwide! As the ever changing landscape of CF brings new hope and new challenges, they stand united to empower our CF Warriors and their families. Read the Warrior Wednesday Impact Report...
by Bonnell Foundation | Feb 13, 2018 | News
February 12, 2018 — Vertex announced that the U.S. FDA approved SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of...
by Bonnell Foundation | Feb 5, 2018 | News
January 31, 2018 — Vertex announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis (CF). This decision was based on...
by Bonnell Foundation | Jul 6, 2015 | News
Via CNBC The U.S. Food and Drug Administration said Thursday it had approved the use of Vertex Pharmaceuticals’ Orkambi, a drug aimed to treat patients with cystic fibrosis, on patients who are at least 12 years old. The company’s shares were temporarily...
by Bonnell Foundation | Aug 1, 2012 | Featured, News
Some health concerns if your child is taking Kalydeco. Read more. Click here: http://www.fda.gov/Drugs/DrugSafety/ucm316693.htm Please check back or email us with any questions. info@roadmaptocf.org
by Bonnell Foundation | Jul 30, 2012 | News
UMHS one of six Michigan facilities linked to New Hampshire hepatitis C investigation The Michigan Department of Community Health has been investigating the employment history of a Hepatitis C-positive health care worker who was recently arrested in New Hampshire for...